CureVac disappoints in COVID vaccine trial - Listen - Nature

CureVac disappoints in COVID vaccine trial

Listen now

Description

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development. News: CureVac COVID vaccine let-down spotlights mRNA design challenges News Feature: How COVID unlocked the power of RNA vaccines Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. See acast.com/privacy for privacy and opt-out information.

More Episodes

See all »

Talking about sex and gender doesn't need to be toxic

Ever since scientific enquiry began, people have focused mainly on men, or if studies involve animals, on male mice, male rats or whatever it may be. And this has led to gaps in scientists’ understanding of how diseases, and responses to treatment, and many other things might vary between people...

Published 05/02/24

Dad's microbiome can affect offsprings' health — in mice

In this episode: 00:46 Using genomics to explain geographic differences in cancer riskThe risk of developing cancer can vary hugely depending on geographic region, but it’s not exactly clear why. To get a better idea, a team has compared the genomes of kidney cancers taken from people around the...

Published 05/01/24

Nature Podcast

Published 05/01/24